Antidiabetic PPARγ-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease
Year: 2003
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Authors: Nikolaus Marx, Johannes Froehlich, Laila Siam, Jochen Ittner, Gerhard Wierse, Arnold Schmidt, Hubert Scharnagl, Vinzenz Hombach, Wolfgang Koenig
Institutions: University of Freiburg, Universität Ulm
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2112546342
